Suppr超能文献

正常人垂体、无功能垂体腺瘤和生长激素瘤中多巴胺受体亚型的表达分析,以及肢端肥大症中多巴胺和生长抑素受体与奥曲肽长效释放制剂临床反应之间的关联。

Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly.

作者信息

Neto Leonardo Vieira, Machado Evelyn de O, Luque Raul M, Taboada Giselle F, Marcondes Jorge B, Chimelli Leila M C, Quintella Leonardo Pereira, Niemeyer Paulo, de Carvalho Denise P, Kineman Rhonda D, Gadelha Mônica R

机构信息

Endocrinology Section, Universidade Federal do Rio de Janeiro, Rio de Janeiro 21941-913, Brazil.

出版信息

J Clin Endocrinol Metab. 2009 Jun;94(6):1931-7. doi: 10.1210/jc.2008-1826. Epub 2009 Mar 17.

Abstract

CONTEXT

Dopamine receptor (DR) and somatostatin receptor subtype expression in pituitary adenomas may predict the response to postsurgical therapies.

OBJECTIVES

Our objectives were to assess and compare the mRNA levels of DR1-5 and somatostatin receptors 1-5 in normal pituitaries (NPs), nonfunctioning pituitary adenomas (NFPAs), and somatotropinomas. In addition, we determined whether the level of DR expression correlates with the in vivo response to octreotide-LAR in acromegalic patients.

DESIGN AND PATIENTS

Eight NPs, 30 NFPAs, and 39 somatotropinomas were analyzed for receptor mRNA levels by real-time RT-PCR. The DR2 short variant was estimated as the DR2 long/DR2 total (DR2T). The relationship between DR expression and the postsurgical response to octreotide-LAR was assessed in 19 of the acromegalic patients.

RESULTS

DR3 was not detected. The relationship between expression levels of DR subtypes in NPs and somatotropinomas was DR2T>>>DR4>>DR5>DR1, whereas in NFPAs, DR2T>>>DR4>>DR1>DR5. The DR2 short variant was the predominant DR2 variant in the majority of samples. In acromegalics treated with octreotide-LAR, DR1 was negatively correlated with percent GH reduction (3 months: r = -0.67, P = 0.002; and 6 months: r = -0.58, P = 0.009), and DR5 was positively correlated with percent IGF-I reduction (3 months: r = 0.55, P = 0.01; and 6 months: r = 0.47, P = 0.04).

CONCLUSIONS

DR2 is the predominant DR subtype in NPs, NFPAs, and somatotropinomas. The fact that DR1, DR4, and DR5 are also expressed in many adenomas tested suggests that these receptors might also play a role in the therapeutic impact of postsurgical medical therapies in patients with NFPA and acromegaly. This was supported by the finding that the in vivo response to octreotide-LAR was negatively associated with DR1 and positively associated with DR5.

摘要

背景

垂体腺瘤中多巴胺受体(DR)和生长抑素受体亚型的表达可能预测术后治疗反应。

目的

我们的目的是评估和比较正常垂体(NP)、无功能垂体腺瘤(NFPA)和生长激素瘤中DR1 - 5和生长抑素受体1 - 5的mRNA水平。此外,我们确定了DR表达水平是否与肢端肥大症患者对长效奥曲肽的体内反应相关。

设计与患者

通过实时逆转录聚合酶链反应(RT - PCR)分析8个NP、30个NFPA和39个生长激素瘤的受体mRNA水平。DR2短变体估计为DR2长/DR2总量(DR2T)。在19例肢端肥大症患者中评估DR表达与术后对长效奥曲肽反应之间的关系。

结果

未检测到DR3。NP和生长激素瘤中DR亚型表达水平的关系为DR2T>>>DR4>>DR5>DR1,而在NFPA中,DR2T>>>DR4>>DR1>DR5。DR2短变体是大多数样本中主要的DR2变体。在用长效奥曲肽治疗的肢端肥大症患者中,DR1与生长激素降低百分比呈负相关(3个月:r = - 0.67,P = 0.002;6个月:r = - 0.58,P = 0.009),DR5与胰岛素样生长因子 - I降低百分比呈正相关(3个月:r = 0.55,P = 0.01;6个月:r = 0.47,P = 0.04)。

结论

DR2是NP、NFPA和生长激素瘤中主要的DR亚型。许多测试的腺瘤中也表达DR1、DR4和DR5这一事实表明,这些受体可能在NFPA和肢端肥大症患者术后药物治疗的治疗效果中也发挥作用。对长效奥曲肽的体内反应与DR1呈负相关且与DR5呈正相关这一发现支持了这一点。

相似文献

6
Genetic abnormalities of somatostatin receptors in pituitary tumors.垂体瘤中生长抑素受体的基因异常。
Mol Cell Endocrinol. 2008 May 14;286(1-2):180-6. doi: 10.1016/j.mce.2007.08.013. Epub 2007 Aug 31.

引用本文的文献

8
Molecular targets in acromegaly.肢端肥大症的分子靶点。
Front Endocrinol (Lausanne). 2022 Dec 5;13:1068061. doi: 10.3389/fendo.2022.1068061. eCollection 2022.

本文引用的文献

1
Somatostatin-dopamine ligands in the treatment of pituitary adenomas.生长抑素-多巴胺配体在垂体腺瘤治疗中的应用
Rev Endocr Metab Disord. 2009 Jun;10(2):83-90. doi: 10.1007/s11154-008-9086-0. Epub 2008 Jul 24.
9
Novel insights in dopamine receptor physiology.多巴胺受体生理学的新见解。
Eur J Endocrinol. 2007 Apr;156 Suppl 1:S13-S21. doi: 10.1530/eje.1.02353.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验